

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman,

José Saldanha and Mary M. Bendig

Application No.:

08/700,737

Group Art Unit:

1644

Filed:

August 15, 1996

Examiner:

Ronald B. Schwadron, Ph.D.

Confirmation No.:

4692

Title:

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH  $\alpha 4\beta 7$  INTEGRIN

CERTIFICATE OF MAILING OR TRANSMISSION				
I hereby certify that this correspondence is being deposited with the United States				
Postal Service with sufficient postage as First Class Mail in an envelope addressed				
to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is				
being facsimile transmitted to the United States Patent and Trademark Office on:				
8-8-05				
Date Signature				
Jeanine Bushy				
Typed or printed name of person signing certificate				

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:			
This I	nformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)		
[ ]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).		
[X]	under 37 CFR 1.97(c) together with either:		8
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or		180.00
	[X] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	00000013 08700737	180
[ ]	under 37 CFR 1.97(d) together with:	0013	
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and	8	
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)	HMARZ11	
[ ]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application file. (Filed after payment of issue fee)	8/12/2005 HMARZI1	2 FC:1806

State	ment Un	der 37 CFR 1.97(e)				
[]	any co	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
[]	comm knowl in the	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
State	ment Un	der 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 200	00			
[ ]	comm was n	tem of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication treceived by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.	n			
[X]	Enclo	Enclosed herewith is form PTO-1449:				
	[X]	Copies of the cited references are enclosed.				
		[ ] Copies of issued U.S. patents and published U.S. applications are not required are not being provided.	ıd			
	[ ]	Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]	3. C			
	[ ]	[ ] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.				
	[ ]	The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:	]			
		[ ] the explanation provided on the attached sheet.				
		[ ] the explanation provided in the Specification.				
		[ ] submission of the enclosed International Search Report.				
		[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.				
		[ ] the enclosed English language abstract.				

[ ]	Applic	cant requests that the following n	on-published pending applic	cations be considered:	
Examiner's Initials		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		Examiner	Date	_	
	[ ] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.				
	[ ]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.			
		r is requested to return a copy of re considered with the next offic		plications indicating which	
It is re	quested	that the information disclosed h	erein be made of record in the	nis application.	
Metho	d of pa	yment:			
[X]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.				
[]	Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.				
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.				
		F	Respectfully submitted,		
			Robert H. Underwood, Ph. Registration No.: 45,179 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	dluvod D.	

Concord, MA 01742-9133
Dated: August 9, 2005

GROUP

1644

PTO-1449 REPRODUCED

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

August 9, 2025 AUS 1 1 2005

(Use several sheets if nucessary)

ATTORNEY DOCKET NO. 1855.1017-000

FIRST NAMED INVENTOR Paul D. Ponath

FILING DATE August 15, 1996

APPLICATION NO.

08/700,737

EXAMINER
Ronald B. Schwadron, Ph.D.
CONFIRMATION NO.
4692

- Vilage			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Cl	Feagan, Brian G., et al., "Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ Integrin," The New England Journal of Medicine, 352(24):2499-2507 (2005).	
	C2	Shaw, Denise R., et al., "Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses," Journal of the National Cancer Institute, 80(19):1553-1559 (1988).	
:	С3		
	C4		
	C5		
	C6		
	C7		
	C8		
	С9		
	C10		
	C11		
	C12		
	C13		
	C14	·	
	C15		
	C16		

EXAMINER	DATE CONSIDERED	
1 2702.111011	DATE CONSTRUCTED	
11	1	
il		

m 1 34